Adjustment of everuximab dosage: flexible treatment according to the condition

Evinacumab (trade name: Evkeeza) is an innovative treatment drug for homozygous familial hypercholesterolemia (HoFH). By blocking the function of ANGPTL3 protein, it effectively reduces the level of low-density lipoprotein cholesterol (LDL-C) in the blood, thereby reducing the risk of cardiovascular disease. During the treatment process, the dosage of everevuximab needs to be flexibly adjusted according to the patient's specific condition to achieve the best therapeutic effect.

The recommended dose of evesumumab is 15mg/kg administered once monthly (every 4weeks) by intravenous infusion over 60 minutes. This is the standard treatment plan based on data from multiple clinical trials and is suitable for most patients with HoFH.

Every patient’s specific condition, physical condition, and response to medications are different. Therefore, the dosage of everuximab needs to be adjusted according to the individual patient's condition. Doctors should comprehensively consider the patient's age, weight, LDL-C level, comorbidities and other factors to formulate a personalized treatment plan.

During the treatment process, doctors should closely monitor the patient's LDL-C levels, liver function indicators and other related biochemical indicators. By regularly evaluating the treatment effects and adverse reactions, the dosage of evesumumab can be adjusted in a timely manner to ensure the safety and effectiveness of the treatment.

If the patient'sLDL-C levels are poorly controlled or adverse reactions worsen, doctors should flexibly adjust the dosage of everevuximab. For example, for patients whose LDL-C levels continue to rise, appropriate increases in medication dosage or shortening of medication intervals may be considered; for patients with severe adverse reactions, it may be necessary to reduce medication dosage or temporarily discontinue medication.

Reference materials:https://www.drugs.com/mtm/evinacumab.html

xa0